LAURUSLABS Q1 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,182 Cr
verified against source
Revenue YoY
-23%
reported change
EBITDA
₹168 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs reported a challenging Q1 FY24 with INR 1,182 crore revenue (down 23% YoY) and 14.2% EBITDA margin (vs ~28-29% in prior year), significantly below expectations. The underperformance stems from lower ARV formulation revenues due to global agency procurement timing shifts, pricing erosion in ARVs, and operational deleverage from reduced volumes. Gross margin at 50.6% indicates base business health remains intact, with margin compression primarily driven by fixed cost deleverage. Management characterizes Q1 as "transient" and expects recovery from Q2 onwards based on order book visibility for ARV formulations and APIs. FY2024 is maintained as a "consolidation year" with no specific revenue/EBITDA guidance. Key growth drivers for FY25+ include CDMO pipeline (60+ active projects), Laurus Bio expansion (R2 debottlenecking in Q3, R3 greenfield), animal health commercial supply starting H2 FY25, and the new multi-year crop science contract. Risk: margin recovery to 28-29% levels requires FY25, and CDMO execution on larger clinical-phase projects remains critical to watch.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects Q2 revenues to improve from Q1 levels based on ARV formulation order book visibility and sequential volume improvement in APIs and formulations.
- FY2024 remains a consolidation year with no change to prior guidance; management indicates they are on par with or better than internal targets.
- FDF capacity utilization expected to increase from 5 billion to 7 billion units by FY24 year-end as brownfield expansions come online.
- Animal health site commercial validations begin October 2023; meaningful revenue contribution expected from H2 FY25 with full-year impact in FY25.
Risks flagged
- EBITDA margin recovery to 28-29% levels will not occur in FY24; management expects gradual improvement requiring FY25 to achieve historical margins. Q1 margin of 14.2% reflects severe operational deleverage.
- While Q1 pricing erosion was minimal, prior year severe price cuts continue to impact revenues. Competition creating pricing headwinds in formulations despite stable volumes.
- Management declined to break down CDMO revenues by segment (human health vs. animal health vs. crop science) or provide revenue trajectory guidance for the next 2-3 years, making pipeline assessment difficult.
- FY25 CapEx guidance deferred to September results; net debt expected to increase by INR 300-400 crore by March 2024 before declining in FY25. R3 equipment orders not yet placed (expected Q2), creating timeline uncertainty.
Key quotes
- We believe this is very transient and underlying demand for our key growth portfolio remains strong. We believe both our API business and FDF business will return to normal levels from Q2 itself.
- Whatever we have indicated as a consolidation year, there is no change in the state. In fact, we are on par with our internal targets, or maybe we are better than our internal targets for the quarter.
- Going back to healthy margins of 28%-29% will need, not just this year, maybe we will achieve during the next financial year.
Research modules